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incidence
Gastrointestinal stromal tumors (GIST) are rare tumors, with
an estimated incidence of 1.5/100 000/year.
diagnosis
When GIST present as a small esophago-gastric or duodenal
nodule £2 cm in size, endoscopic biopsy may be difficult, and
laparoscopic/laparotomic excision may be the only way to get
to a histologic diagnosis. Many of these small nodules are low-
risk GIST or other non-malignant entities. Therefore, the
standard approach to these patients is endoscopic ultrasound
and then follow-up, reserving excision for patients whose
tumor increases in size. Alternatively, the decision can be
shared with the patient to make a histologic assessment. On the
other hand, the standard approach to nodules >2 cm in size is
biopsy/excision, because, if GIST, they imply a higher risk. The
standard approach to rectal (or recto-vaginal space) nodules is
biopsy/excision after ultrasound assessment regardless of the
tumor size, because the risk is higher and the local implications
for surgery are more critical. However, a follow-up policy may
be an option, shared with the patient in the case of small
lesions.
If there is an abdominal nodule not amenable to endoscopic
assessment, laparoscopic/laparotomic excision is the standard
approach. If there is a bigger mass, especially if surgery is likely
to be a multivisceral resection, multiple core needle biopsies are
the standard approach. This may let the surgeon plan the best
approach according to the histologic diagnosis and may avoid
surgery for diseases which do not merit it (e.g. lymphomas,
mesenteric fibromatosis, germ cell tumors). The risk of
peritoneal contamination is negligible if the procedure is
properly carried out. Lesions at risk in this regard (e.g. cystic
masses) should be biopsied in specialized centers. Immediate
laparoscopic/laparotomic excision is an alternative on an
individualized basis, especially if surgery is limited.
If a patient presents with conspicuous metastatic disease,
then a biopsy of the metastatic focus is sufficient and the
patient usually does not require a laparotomy for diagnostic
purposes.
The tumor sample should be fixed in formalin (Bouin
fixation should be avoided, since it may impair the feasibility of
molecular analysis). Frozen tissue collection is encouraged,
because new molecular pathology assessments may become
available later on and be made in the patient’s interest.
Appropriate informed consent should be sought to allow for
later analysis and further research.
Pathologically, the diagnosis of GIST relies on morphology
and immunohistochemistry. CD117 is generally positive,
although a proportion of true GIST (in the 5% range) are
CD117-negative. Antigen retrieval may result in false positive
CD117 staining. Mitotic count has prognostic value, and
should be expressed as number of mitoses per 50HPF.
Mutational analysis for known mutations involving KIT and
PDGFRA genes can confirm the diagnosis of GIST, if doubtful
(particularly in CD117-negative suspect GIST). In addition,
mutational analysis has predictive and prognostic value, so that
it is strongly recommended in the diagnostic work-up of all
GIST. Centralization of mutational analysis in a laboratory
enrolled in an external quality assurance program and with
expertise in the disease may be useful in order to make
mutational analysis more widely available.
staging and risk assessment
The risk of relapse may be estimated on the basis of some
prognostic factors, which should be recorded on a standard
basis: mitotic rate, tumor size, tumor site, surgical margins
(including whether tumor rupture occurred).
Tumor size and mitotic count are considered by the 2002
Consensus risk classification. This was correlated with
prognosis in an epidemiological study, showing that the ‘high
risk’ category has a much worse prognosis than the others.
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‘Very low risk’ and ‘low risk’ categories have a very favorable
prognosis. The ‘intermediate risk’ category probably does not
discriminate well and includes cases at both low and high risk.
A more recently proposed risk partitioning incorporates
tumor site in addition to the mitotic count and tumor size. In
particular, it reflects the fact that gastric GIST have a better
prognosis than small bowel or rectal GIST. The risk estimate for
subgroups is based on a single retrospective analysis, and
therefore needs confirmation. However, this classification
better distinguishes across different risk levels.
Tumor rupture, whether spontaneous or at the time of
surgical resection, should be recorded, because it denotes
a highly adverse prognostic value due to peritoneal
contamination. However, it is uncertain whether these patients
should be considered metastatic. Abdominal washing during
surgery may be an option in case of tumor rupture. Careful
surgical exploration for small peritoneal nodules is important.
Staging procedures take into account the fact that most
relapses affect the peritoneum and the liver. Contrast-enhanced
abdominal and pelvic CT scan is of choice for staging and
follow-up. MRI may be an alternative. For rectal GIST, MRI
provides better preoperative staging information. Chest CT
scan or X-rays and routine laboratory testing complement the
staging work-up of the asymptomatic patient. Evaluation of
FDG uptake using PET scan, or PET–CT/MRI, is useful mainly
when early detection of tumor response to imatinib treatment
is of special concern.
treatment
Multidisciplinary treatment planning is needed (involving
pathologists, radiologists, surgeons, medical oncologists), such
as that which is available in referral centers for sarcomas and
GIST, and/or within collaborative networks sharing
multidisciplinary expertise.
limited disease
Standard treatment of localized GIST is complete surgical
excision, without dissection of clinically negative lymph nodes
[IV, A]. If laparoscopic excision is planned, the technique needs
to follow the principles of oncologic surgery. A laparoscopic
approach is clearly discouraged in patients who have large
tumors. R0 excision is the goal. If an R1 excision has been
made, re-excision may be a choice, provided the original site of
lesion can be found and major functional sequelae are not
foreseen. When R0 surgery implies major functional sequelae,
and preoperative medical treatment has not helped or cannot
be foreseen, the decision can be shared with the patient to
accept R1 margins, particularly for low-risk lesions, in the lack
of a formal demonstration that R1 surgery is associated with
a worse overall survival. Patient referral to a specialized center
should be considered, and R0 resection should be considered as
the reference standard.
If R0 surgery is not feasible, or it might be achieved through
less mutilating surgery in the case of cytoreduction, imatinib
pretreatment is recommended [IV, A]. This may also be the
case if the surgeon believes that the surgical conduct is safer
after cytoreduction (e.g. the risk of bleeding and tumor rupture
is decreased). Following maximal tumor response, generally
after 6–12 months, surgery is performed. Mutational analysis
may help to exclude non-sensitive mutations from therapy with
imatinib. PET scan, or PET–CT/MRI, may be particularly
useful to assess tumor response very rapidly, in terms of a few
weeks, so that surgery is not delayed in the case of non-
responding disease.
The risk of relapse can be substantial, or relatively high, in
many presentations, depending on mitotic count, tumor size
and site of disease. Given the efficacy of imatinib in the disease,
adjuvant treatment with the drug has been studied. Definitive
results are still not available, although an early advantage in
relapse-free survival was reported in a preliminary format, with
a limited follow-up and number of events, by one randomized
study performed in >3 cm localized GIST. The demonstrated
benefit is in terms of early relapse-free survival, so that a longer
follow-up is needed to draw definitive conclusions, in
particular with regard to the absolute relapse rate, the length of
the delay in relapse and the behavior of secondary resistance to
imatinib in relapsing patients. Overall survival, relapse-free rate
at a longer interval, time to secondary resistance are relevant
end-points to take into account in clinical studies open to
accrual or follow-up. Currently, adjuvant imatinib treatment
for GIST patients with localized disease is considered
investigational.
extensive disease
In locally advanced inoperable patients and metastatic patients,
imatinib is standard treatment [IV, A]. This applies also to
metastatic patients who have been completely relieved of all
lesions surgically, being discovered unexpectedly.
Standard dose of imatinib is 400 mg daily [I, A]. Data have
been provided that patients with exon 9 KIT mutations fare
better in terms of progression-free survival on a higher dose
level, i.e. 800 mg daily, which is therefore standard treatment in
this subgroup [III, A]. Treatment should be continued
indefinitely, since treatment interruption is generally followed by
relatively rapid tumor progression in virtually all cases, even
when lesions have been previously surgically excised [II, B]. Dose
intensity should be maintained by proper management of side-
effects and a correct policy of dose reductions and interruptions
in the case of excessive, persistent toxicity. Close monitoring of
tumor response should be continued throughout treatment,
since the risk of secondary progression persists over time.
Complete excision of residual metastatic disease has been
shown to be related to a good prognosis, provided the patient is
responding to imatinib, but it is left to be demonstrated whether
this is due to surgery or to a selection bias. Therefore, surgery
of metastatic responding patients is considered investigational.
The standard approach in the case of tumor progression is to
increase the imatinib dose to 800 mg daily [III, B]. This may be
useful in case of a KIT exon 9 mutated GIST, if the patient
started at 400 mg; probably in case of changes in drug
pharmacokinetics over time (which is amenable to assessment
and constitutes a subject of study); or, possibly, in case of some
secondary molecular alterations. Also patient non-compliance
should be ruled out as a possible cause of tumor progression, as
well as drug interactions with concomitant medications.
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In case of progression or intolerance on imatinib, second-line
standard treatment is sunitinib [II, B]. The drug was proved
effective in terms of progression-free survival following a ‘4
weeks on–2 weeks off ’ regimen. Preliminary data have been
provided that a continuous regimen with a lower daily dose
may be equally effective and possibly better tolerated, so that
this regimen can be an option on an individualized basis.
After failing on sunitinib, the patient with metastatic GIST
should be considered for participation in a clinical trial of new
therapies or new combinations.
Surgical excision of progressing disease has not been
rewarding in published series, but surgery of limited
progression, such as the ‘nodule within a mass’, has been
associated with a progression-free interval in the same range as
for second-line treatment with sunitinib. Therefore, it may be
a palliative option in the individual patient with a limited
progression. Non-surgical procedures (local treatment, such as
ablations, etc.) may be selected.
There is anedoctal evidence that patients who have already
progressed on imatinib may occasionally have a benefit when
rechallenged with the same drug. Likewise, maintaining
treatment with an anti-tyrosine kinase agent even in the case of
progressive disease may slow down progression as opposed to
stopping it, of course if no other option is available at the time.
Therefore, rechallenge or continuation treatment with an anti-
tyrosine kinase agent to which the patient has already been
exposed may be an option in individual cases. On the other
hand, combinations of anti-tyrosine kinase agents should be
discouraged outside of clinical studies, because of the potential
for considerable toxicity.
response evaluation
Antitumor activity translates into tumor shrinkage in the
majority of patients, but some patients may show only changes
in tumor density on CT scan, or these changes may precede
a delayed tumor shrinkage. These changes in tumor radiological
appearance should be considered as tumor response. In particular,
even some increase in tumor size may be indicative of tumor
response if tumor density on CT scan is decreased. Even the
‘appearance’ of new lesions may depend on their being more
evident when becoming less dense. Therefore, both tumor size and
tumor density on CT scan, or consistent changes on MRI, should
be considered as criteria for tumor response. FDG–PET scan has
proved to be highly sensitive in early assessment of tumor
response, and may be useful in doubtful cases, or when early
prediction of response is highly useful (e.g. preoperative
cytoreductive treatments). The absence of tumor progression after
months of treatment equally amounts to tumor response. On the
other hand, also tumor progression may not be accompanied by
changes in tumor size. In fact, some increase in tumor density
within tumor lesions may be indicative of tumor progression.
A typical progression pattern is the ‘nodule within the nodule’, by
which a portion of a responding lesion becomes hyperdense.
follow-up
There are no published data supporting specific policies for
follow-up of surgically treated patients with localized disease.
Relapses most often occur to the peritoneum or in the liver.
The mitotic rate likely affects the speed at which relapses take
place. Risk assessment based on mitotic count, tumor size and
tumor site may help in choosing the routine follow-up policy.
High-risk patients generally relapse within 2–3 years, while low-
risk patients may relapse later, although much less likely. That
said, routine follow-up schedules differ across institutions. As
an example, in some institutions intermediate–high-risk
patients undergo a routine follow-up with CT scan every 3–4
months for 3 years, then every 6 months until 5 years, and
yearly afterwards; for low-risk tumors, follow-up is carried out
with CT scan every 6 months for 5 years. Very low risk GIST
probably do not deserve routine follow-up, although one must
be aware that the risk is not nil.
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as used by the American Society of Clinical Oncology are
given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts and
the ESMO faculty.
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